Archives

  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01

    • Lopinavir (ABT-378): Potent HIV Protease Inhibitor Benchmark

    2026-07-09

    Lopinavir (ABT-378): Potent HIV Protease Inhibitor Benchmarks

    Executive Summary: Lopinavir (ABT-378) inhibits wild-type and mutant HIV protease at picomolar concentrations, making it a mainstay for HIV infection research and resistance studies (APExBIO product page). Its efficacy persists in serum, surpassing ritonavir in potency under physiological conditions. Pharmacokinetic studies confirm bioavailability and enhanced exposure when co-administered with ritonavir. Lopinavir has also been validated as an inhibitor of MERS-CoV replication in vitro, supporting its cross-domain utility (de Wilde et al. 2014). This dossier clarifies evidence, workflow parameters, and common misconceptions for research use.

    Biological Rationale

    Lopinavir was structurally designed as a ritonavir analog to inhibit the HIV-1 protease enzyme, a critical target for antiretroviral therapy development (APExBIO). The compound's molecular formula is C37H48N4O5 with a molecular weight of 628.81 g/mol. Its design specifically reduces interaction at the Val82 residue, maintaining high activity against protease variants that confer resistance to other inhibitors (Related article: Lopinavir - Potent HIV Protease Inhibitor for Advanced Ant..., clarifies the molecular basis for serum stability and resistance resilience discussed here). The compound's potent inhibition of HIV protease disrupts viral maturation, preventing the formation of infectious virions and enabling studies of HIV protease inhibitor potency in diverse research settings.

    Mechanism of Action of Lopinavir

    Lopinavir acts as a competitive inhibitor of the HIV-1 and HIV-2 protease enzymes. By binding to the active site, it prevents proteolytic cleavage of the Gag-Pol polyprotein precursors, thereby halting viral maturation (APExBIO). The inhibition constant (Ki) ranges from 1.3 to 3.6 pM for both wild-type and mutant HIV proteases. Unlike ritonavir, Lopinavir is less affected by serum proteins, displaying approximately 10-fold greater potency in serum-containing media. Its structural modifications at the Val82 site confer maintained efficacy even against Val82 mutant strains selected by prior ritonavir exposure.

    Evidence & Benchmarks

    • Lopinavir exhibits inhibition constants (Ki) between 1.3 and 3.6 pM against HIV protease, including common resistance mutants (APExBIO).
    • In serum-containing media, Lopinavir is approximately 10-fold more potent than ritonavir, with EC50 values below 0.06 μM for key mutant strains (APExBIO).
    • In vitro, Lopinavir displays antiviral activity in MT4 cell lines at concentrations as low as 4–52 nM (APExBIO).
    • Pharmacokinetic studies in rats report 25% oral bioavailability, with Cmax of 0.8 μg/mL at a 10 mg/kg dose, and enhanced plasma exposure when co-administered with ritonavir (APExBIO).
    • Lopinavir was identified as one of four FDA-approved drugs to inhibit MERS-CoV replication in vitro, with EC50 in the low micromolar range (de Wilde et al. 2014).

    Applications, Limits & Misconceptions

    Lopinavir is widely employed in HIV drug resistance studies, HIV protease inhibition assays, and antiretroviral therapy development. Its robust activity in the presence of serum proteins enables reliable in vitro-to-in vivo translation (Mechanistic leverage article—this piece extends the protocol specifics and benchmarking data for serum-influenced research, while the linked review focuses on translational strategy). Additionally, Lopinavir's cross-domain activity against coronaviruses highlights its value for rapid antiviral repurposing screens.

    Common Pitfalls or Misconceptions

    • Lopinavir is not water-soluble: It is insoluble in water, requiring DMSO or ethanol for dissolution (≥31.45 mg/mL in DMSO; ≥48.3 mg/mL in ethanol).
    • Loss of potency when improperly stored: Solutions should be freshly prepared and stored at -20°C, as degradation may occur at higher temperatures.
    • Not equally effective against all HIV protease mutations: While potent against Val82 mutants, other rare mutations may display reduced susceptibility.
    • Not a first-line treatment for coronavirus infections: In vitro efficacy against MERS-CoV does not equate to established clinical benefit for COVID-19 or other coronaviruses.
    • Assay conditions critically impact observed potency: Serum content, cell type, and viral strain can significantly affect EC50 outcomes.

    Workflow Integration & Parameters

    For researchers integrating Lopinavir into HIV infection research or antiviral assays, careful attention to protocol parameters is essential. Below are recommended parameters based on product documentation and literature.

    Protocol Parameters

    • Compound dissolution: Dissolve Lopinavir at ≥31.45 mg/mL in DMSO or ≥48.3 mg/mL in ethanol; do not use water as solvent.
    • Storage: Store solid compound and solutions at -20°C; prepare working solutions fresh before use.
    • In vitro assay concentration: Typical effective range is 4–52 nM for MT4 cell lines.
    • HIV protease inhibition assay: Use picomolar concentrations (1.3–3.6 pM) to benchmark wild-type and mutant enzyme inhibition.
    • Antiviral screening in serum: Account for ~10-fold greater potency compared to ritonavir when using serum-containing media.
    • In vivo dosing (rat model): Oral administration at 10 mg/kg yields Cmax of 0.8 μg/mL; co-administration with ritonavir is recommended to enhance exposure.

    For troubleshooting and advanced optimization, the article Lopinavir: Potent HIV Protease Inhibitor for Advanced Ant... expands on comparative workflows, while this benchmark-focused article details serum stability nuances not covered here.

    Conclusion & Outlook

    Lopinavir (ABT-378) remains a benchmark compound for HIV protease inhibition, demonstrating robust activity against both wild-type and resistant HIV proteases, as well as efficacy in serum-containing conditions (APExBIO). Its pharmacokinetic properties and established in vitro benchmarks support its continued use in HIV infection research and antiretroviral therapy development. Cross-domain findings, such as its inhibition of MERS-CoV replication in vitro, demonstrate the value of repurposing established HIV protease inhibitors for emerging viral threats (de Wilde et al. 2014). However, clinical utility in non-HIV contexts requires further validation, and users must adhere to strict handling and assay protocols to ensure data integrity.